Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | TOP2A | P11388 | 5/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863948 | 1.00 | STAT3 (0.56) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL3549628 | 0.90 | STAT3 (0.63) | STAT3ADRB2ALDH1A1KCNH2TOP2A | |
| SCHEMBL7646010 | 0.89 | ALDH1A1 (0.47) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL5704396 | 0.87 | ADRB2 (0.64) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL7978648 | 0.87 | STAT3 (0.59) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL25669900 | 0.86 | ADRB2 (0.58) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL10471225 | 0.85 | STAT3 (0.53) | STAT3ADRB2ALDH1A1KCNH2TOP2A | |
| SCHEMBL25669976 | 0.85 | ADRB2 (0.57) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL7575069 | 0.85 | ADRB2 (0.61) | STAT3ADRB2ALDH1A1POLBCHRM2 | |
| SCHEMBL30468815 | 0.85 | ALDH1A1 (0.57) | ALDH1A1POLBCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989314-B | Method for hydrolyzing quinolone formate | 拜耳动物保健有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117849219-A | Method for detecting content of pramipexole | 上海汉维生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3784656-B1 | PROCESS FOR THE HYDROLYSIS OF QUINOLONE CARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-06-28 | — | — | EP | disclosed |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | BAYER ANIMAL HEALTH GMBH (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | BAYER ANIMAL HEALTH GMBH (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| EP-3784656-A1 | PROCESS FOR THE HYDROLYSIS OF QUINOLONE CARBOXYLIC ESTERS | Bayer Animal Health GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| CN-107987074-B | Synthetic method of prafloxacin | 浙江美诺华药物化学有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111989314-A | Process for hydrolysis of quinolone formates | 拜耳动物保健有限责任公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | LYNCHEM CO., LTD. (CN) | 2003-09-04 | — | — | US | disclosed |
| EP-1319656-A1 | A NEW PROCESS FOR PREPARING A QUINOLONE-CARBOXYLIC ACID | Lynchem Co., Ltd. (CN) | 2003-06-18 | — | — | EP | disclosed |
| US-6432948-B1 | ANTIULCER AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6133260-A | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| US-5190955-A | Bactericides, effective against antibiotic resistant germs | BAYER AKTIENGESELLSCHAFT (DE) | 1993-03-02 | — | — | US | disclosed |
| US-5051418-A | Antibacterial 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | disclosed |
| US-4956465-A | Bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-09-11 | — | — | US | disclosed |
| US-4908366-A | Bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | CYP4B1, QPCT, NQO2 | STAT3 4231/4885ADRB2 1061/4885ALDH1A1 95/4885 |
| US-20210078950-A1 | METHOD FOR THE HYDROLYSIS OF QUINOLONECARBOXYLIC ESTERS | NQO2, PGD, ALAD | STAT3 4531/4885ADRB2 2182/4885ALDH1A1 274/4885 |
| US-11332444-B2 | Method for the hydrolysis of quinolonecarboxylic esters | NQO2, PGD, ALAD | STAT3 4531/4885ADRB2 2182/4885ALDH1A1 274/4885 |
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | STAT3 1093/4885ADRB2 2223/4885ALDH1A1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.